T
recent Japanese guidelines. All patients gave informed consent for the procedure, which was approved by the institutional review board. Statistical analysis was performed using SPSS (SPSS Inc, Chicago, IL, USA). Data are expressed as a number (%) or mean values ± SD. Continuous variables were compared with Wilcoxon nonparametric testing or Mann-Whitney testing. Simple linear regression analysis was used to assess the correlation between late lumen loss after the 6-month follow-up and clinical and angiographic factors. Multivariate linear regression analysis was performed to identify independent predictors of changes in the MLD after the 6-month follow-up, and the variables included in the final model were selected by stepwise analysis. Statistical significance was defined as a p-value <0.05.
Results
The baseline clinical and angiographic characteristics of all patients are shown in Tables 1 and 2 . Restenosis of balloon angioplasty, chronic total occlusion, bifurcation and calcified lesions were 4 (8%), 5 (10%), 5 (10%) and 2 (4%) of the total lesions, respectively. The average '6-month follow-up' and late follow-up after stenting were 180.0±58.3 days and 449.7±156.1 days. The characteristics of the implanted stents were (1) size of 2.98±0.44 mm and (2) length of 18.0±5.1 mm, and the deployment pressure was 12.2±2.3 atm. The balloon/artery ratio was 1.25±0.20. Serial quantitative coronary angiographic results are shown in Table 2 . Lesion lengths at 6-month follow-up and after follow-up were 7.77±3.78 mm and 6.94±3.98 mm, respectively. The angiographic restenosis (% diameter stenosis >50%) rate after the 6-month follow-up was identical to the rate at the 6-month follow-up (7.8%). There were no significant changes between the parameters of quantitative coronary angiography at and after the 6-month, nor did the parameters differ between the patients with or without acute coronary syndrome. Eight lesions regressed and 6 progressed, when regression and progression were defined as a change in the MLD greater than 0.4 mm after the 6-month follow-up. Two lesions (3.9%) required target lesion revascularization because of in-stent restenosis at the late follow-up.
Simple linear regression analysis demonstrated that late luminal loss after the 6-month follow-up inversely correlated with late loss at the 6-month follow-up (r=-0.42, p=0.0025) (Fig 1) . The late luminal loss after the 6-month follow-up also correlated with the MLD at 6 months (r=0.28, p=0.047) (Fig 2) ; however, there was no significant correlation between the late lumen loss after the 6- (Table 3) .
Older age, diabetes, hyperlipidemia, smoking and small stent diameter (<3.0 mm) were also associated with late luminal reduction, whereas a bifurcation lesion and small MLD at the 6-month follow-up were associated with late luminal recovery. Deployment pressure was not associated with the late luminal modification.
Discussion
We have shown that late luminal loss after the 6-month follow-up of stenting significantly correlated with the MLD and late loss at the 6-month follow-up. Age, diabetes, hyperlipidemia, smoking, bifurcation lesion, small stent diameter and the MLD at the 6-month follow-up were predictors of late luminal modification.
There is controversy about changes in the lumen dimensions beyond 6 months after stenting. Studies performed with the Palmaz-Schatz stent showed no significant changes between 6 and 12 months, 3 whereas 2 reports of the next generation stents demonstrated a significant increase in the MLD after 6 months. 4, 5 Recently, an angiographic study 6 and an intravascular ultrasound study 7 of contemporary stents also demonstrated regression of intimal hyperplasia between 6 and 12 months. However, our results of quantitative coronary angiography did not show a significant change and this discrepancy may be attributable to differences in the amount of intimal hyperplasia at the 6-month follow-up because late regression correlates with the amount of intimal hyperplasia. 3, 4, 6 We did not include cases of in-stent restenosis with myocardial ischemia at the 6-month follow-up, thus the late loss at the 6-month followup was less than in previous reports. Therefore in this study, the MLD after the 6-month follow-up was not significantly different from the MLD at the 6-month follow-up. Our results confirmed the significant correlation between late luminal loss after the 6-month follow-up and the amount of intimal hyperplasia at the 6-month followup, but did not show that all lesions would regress beyond 6 months. Our results concurred with previous reports that the MLD in some lesions would decrease even after 6 months. 4, 6 In our study, late loss and the MLD at 6-month follow-up correlated significantly with late lumen loss after the 6-month follow-up; however, on multivariate analysis late loss at the 6-month follow-up was not a predictor of late luminal loss after 6 months, whereas the MLD at the 6-month follow-up was a significant predictor. Because late loss at the 6-month follow-up also correlated with the MLD at the 6-month follow-up (r=-0.475, p=0.0004), this correlation might contribute to the significant correlation between late loss at the 6-month follow-up and late lumen loss afterward.
The mechanism of late luminal changes remains unclear, but an animal study showed that a reduction in the proteoglycan content and a change in the subtype of collagen were attributable to late luminal recovery. 8 A human study demonstrated that smooth muscle cell density was reduced, and that water-trapping proteoglycans and type III collagen were replaced with decorin and type I collagen after 18 months since stenting. 9 That result suggests that the extracellular matrix is also important in the late luminal modifications in humans. The mechanism of extracellular matrix accumulation is also unclear, but decreased matrix metalloproteinase activity in diabetes has been reported, 10 which may be one of the mechanisms of late luminal progression in diabetes.
We have demonstrated for the first time the clinical predictors of late luminal changes after 6 months. Previous studies have revealed that the rate of restenosis after coronary stenting in patients with diabetes and small coronary arteries is higher, but that the clinical factors of age, hyperlipidemia, smoking were not significant predictors of stent restenosis. 11, 12 Therefore, it is interesting that these clinical factors, which are strong risk factors of coronary artery disease, 13 were predictors of late luminal changes after 6 months. The incidence of a bifurcation lesion has been identified as a strong independent predictor of restenosis, 14 but in our study a bifurcation lesion was a predictor of late luminal recovery, thus the mechanism of luminal modification within 6 months and then after 6 months of the stent placement may differ. The predictors demonstrated in the present study have clinical implications. When a moderate narrowing is found at 6 months after stenting and the patient is asymptomatic, it may be appropriate to develop a strategy based on the clinical predictors. Moderate restenosis after implantation of a small-sized stent in a patient with multiple risk factors of age, diabetes, hyperlipidemia and smoking may need follow-up at 12 months. On the other hand, a low-risk patient with a large-sized stent of 3.0 mm or more may be safely observed. A bifurcation lesion may also not need late follow-up. Indeed, the 2 patients in this study who required target lesion revascularization after the 6-month follow-up had multiple predictors; one was a smoker and had been implanted with a 2.5-mm stent, and the other had diabetes mellitus and hyperlipidemia. A prospective study is needed to determine whether this strategy is useful in clinical situations.
It has been reported that restenosis may be influenced by the stent's characteristics. 15 In particular, the thickness of the stent struts has been recently suggested as influencing neointimal growth, and that thicker struts are associated with higher restenosis rates than stents with thinner struts. 1, 2 Late lumen enlargement occurs between 6 and 12 months after implantation of stents with thicker strut, 6, 7 but not after implantation of the thinner strut stents. 3 Thus, we used a type of thicker strut stent, the S670/660 stent system, which has a highly flexible modular design consisting of interconnected sinusoidal rings.
In conclusion, older age, diabetes mellitus, hyperlipidemia, smoking and a small stent diameter were associated with late luminal reduction beyond 6 months after implantation of a thicker strut type of coronary stents, whereas a bifurcation lesion and small MLD at the 6-month follow-up were associated with late luminal recovery.
